



Denali Therapeutics Appoints Dana Andersen, Ph.D., as Chief Technical and Manufacturing Officer

August 7, 2018

SOUTH SAN FRANCISCO, Calif., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today announced that Dr. Dana Andersen has joined the company as Chief Technical and Manufacturing Officer.

Dr. Andersen joins Denali from Genentech, where he served in various roles for nearly 23 years, working most recently as Vice President and Global Head of Technical Development Project & Portfolio Management. Prior to this role, he was Vice President of Pharmaceutical Development and held numerous leadership roles spanning biologics manufacturing process development at Genentech.

Dr. Andersen is a fellow of the American Institute for Medical and Biological Engineering and received a B.S. from the University of Colorado at Boulder, and a M.S. and Ph.D. from Stanford University, all in chemical engineering with a focus on biological systems.

"I am thrilled to join Denali's team to help advance a promising portfolio of small and large molecules addressing neurodegenerative disease," said Dr. Andersen.

"With our progressing portfolio, including our ATV and ETV platforms that are designed to deliver large molecules across the blood-brain barrier, we are pleased to welcome Dana to Denali. Dana brings a wealth of experience in technical development of both large and small molecule manufacturing, as well as deep leadership experience. Dana will further build and scale our internal manufacturing organization and lead our external technical and manufacturing collaborations," said Ryan Watts, Ph.D., CEO.

About Denali

Denali is a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases. Denali pursues new treatments by rigorously assessing genetically validated targets, engineering delivery across the blood-brain barrier and guiding development with biomarker monitoring to demonstrate target engagement and select patients. Denali is based in South San Francisco. For additional information, please visit www.denalitherapeutics.com.

Contacts:

Morgan Warners
(202) 337-0808
mwarners@gpg.com

OR

Lizzie Hyland
(646) 495-2706
lhyland@gpg.com

 [Primary Logo](#)

Source: Denali Therapeutics Inc.